Discipline, Diversification, Liquidity, Consistency.
Top Stories
- Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential
- National Australia Bank flags $503 million impairment hit on Mideast volatility
- Travere Therapeutics (TVTX) Climbs 40.8% on Filspari Approval
- Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30
- Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29